ShanuModiMD

PubMed

• First-in-Human Evaluation of Site-Specifically LabeledZr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
  Randy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, Audrey Mauguen, Ryan Min, Sue Park, Julia P Brockway, Jacqueline F Bromberg, W Iris Zhi, Mark E Robson, Rache...> ;Journal of Nuclear Medicine. 2024 Mar 1
• Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
  Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung-Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Oku...> ;Japanese Journal of Clinical Oncology. 2024 Apr 6
• 2 citations
  The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
  Lewis, G., Li, G., Guo, J., Yu, S., Fields, C., Lee, G., Zhang, D., Dragovich, P., Pillow, T., Wei, B., Sadowsky, J., Leipold, D., Wilson, T., Kamath, A., Mamounas, M....> ;Nature Communications. 2024 Jan 11
• 1 citations
  Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
  Marra, A., Chandarlapaty, S., Modi, S.> ;Nature Reviews. Clinical Oncology. 2024 Mar 1
• 3 citations
  Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consoli...
  Tsai, C., Yang, J., Shaverdian, N., Patel, J., Shepherd, A., Eng, J., Guttmann, D., Yeh, R., Gelblum, D., Namakydoust, A., Preeshagul, I., Modi, S., Seidman, A., Train...> ;Lancet. 2024 Jan 13
• Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.
  Nelson S Moss, Jolene M Singh, Anne S Reiner, Joshua Z Drago, Shanu Modi, Andrew D Seidman, Sarat Chandarlapaty, Dara S Ross> ;NPJ Breast Cancer. 2023 Oct 23
• 2 citations
  Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.
  Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, Shawn Lucas, Maha Karnoub, Matthew T Olson, David G Hicks, Gary Tozbikian, Aleix Prat, Naoto T Ueno, Shanu Modi, Wen...> ;Virchows Archiv. 2023 Oct 20
• Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
  Stephanie Gu, Stephen Dusza, Elizabeth Quigley, Helen Haliasos, Alina Markova, Michael Marchetti, Andrea P Moy, Chau Dang, Shanu Modi, Diana Lake, Sarah Noor, Mario E ...> ;Breast Cancer Research and Treatment. 2024 Jan 1
• 6 citations
  Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation.
  Anna Rodina, Chao Xu, Chander S Digwal, Suhasini Joshi, Yogita Patel, Anand R Santhaseela, Sadik Bay, Swathi Merugu, Aftab Alam, Pengrong Yan, Chenghua Yang, Tanaya Ro...> ;Nature Communications. 2023 Jun 23
• 33 citations
  ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
  P Tarantino, G Viale, M F Press, X Hu, F Penault-Llorca, A Bardia, A Batistatou, H J Burstein, L A Carey, J Cortes, C Denkert, V Diéras, W Jacot, A K Koutras, A Lebeau...> ;Annals of Oncology. 2023 Aug 1
• Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients.
  Stephanie Gu, Stephen Dusza, Elizabeth Quigley, Helen Haliasos, Alina Markova, Michael Marchetti, Andrea Moy, Chau Dang, Shanu Modi, Diana Lake, Sarah Noor, Mario Laco...> ;Research Square. 2023 Apr 28
• 7 citations
  Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
  Jessica M Scott, Jasme Lee, James E Herndon, Meghan G Michalski, Catherine P Lee, Kelly A O'Brien, John P Sasso, Anthony F Yu, Kylie A Rowed, Jacqueline F Bromberg, Ti...> ;European Heart Journal. 2023 Dec 7
• 1 citations
  Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.
  Charlie Yang, Christine Brezden-Masley, Anil Abraham Joy, Sandeep Sehdev, Shanu Modi, Christine Simmons, Jan-Willem Henning> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
• 18 citations
  Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
  Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A Hurvitz, Shanu Modi, Fabrice Andre, Ian E Krop, Xavier Gonzàlez Farré, Benoit You, Cristina Saura, Sung-Bae K...> ;Cancer Discovery. 2022 Dec 2
• 7 citations
  Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
  Elaine M Walsh, Ayca Gucalp, Sujata Patil, Marcia Edelweiss, Dara S Ross, Pedram Razavi, Shanu Modi, Neil M Iyengar, Rachel Sanford, Tiffany Troso-Sandoval, Mila Gorsk...> ;Breast Cancer Research and Treatment. 2022 Oct 1
• 12 citations
  Beyond HER2: Targeting the ErbB receptor family in breast cancer.
  Joshua Z Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi> ;Cancer Treatment Reviews. 2022 Sep 1
• 58 citations
  Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
  C A Powell, S Modi, H Iwata, S Takahashi, E F Smit, S Siena, D-Y Chang, E Macpherson, A Qin, J Singh, C Taitt, N Shire, D Ross Camidge> ;ESMO Open. 2022 Aug 1
• 2 citations
  Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan.
  Nelson S Moss, Umberto Tosi, Bianca D Santomasso, Kathryn Beal, Shanu Modi> ;CNS Oncology. 2022 Sep 1
• 12 citations
  Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases.
  David B Page, Kathryn Beal, Stefanie N Linch, Kateri J Spinelli, Micaela Rodine, Darragh Halpenny, Shanu Modi, Sujata Patil, Robert J Young, Thomas Kaley, Taha Merghou...> ;NPJ Breast Cancer. 2022 Apr 19
• 7 citations
  Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
  Emanuela Ferraro, Jasmeet Singh, Sujata Patil, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Andrea V Barrio, Rachna Malani, Ingo K Mellinghoff, Adrienne Boire, Hann...> ;NPJ Breast Cancer. 2022 Mar 22
• 3 citations
  Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates
  Julia Canestraro, Malin Hultcrantz, Shanu Modi, Paul A. Hamlin, Alexander N. Shoushtari, Jason A. Konner, William P. Tew, Neil M. Iyengar, Murk Heinemann, David H. Abr...> ;Cornea. 2021 Nov 24
• 117 citations
  Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
  Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortes, Jean-Charles Soria, Giuseppe Curigliano> ;CA. 2021 Nov 12
• 57 citations
  Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review
  Paolo Tarantino, Shanu Modi, Sara M. Tolaney, Javier Cortes, Erika Hamilton, Sung-Bae Kim, Masazaku Toi, Fabrice Andre, Giuseppe Curigliano> ;JAMA Oncology. 2021 Oct 14
• 92 citations
  Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
  Emanuela Ferraro, Joshua Z. Drago, Shanu Modi> ;Breast Cancer Research. 2021 Aug 11
• 12 citations
  Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
  Shanu Modi> ;Future Oncology. 2021 Sep 1
• Join now to see all

Lectures

• A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator’s choice in HER2-low breast cancer. 
  2019 ASCO Annual Meeting - 6/1/2019
• Less Is More: A Targeted Difference 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018